Vincristine by continuous infusion in refractory breast cancer

Hopkins, JO; Dv, Jackson; Dr, White; Hb, Muss; Richards, Fred; Mr, Cooper; Jj, Stuart; Cl, Sparr; Hb, Wells

doi:10.1097/00000421-198306050-00003

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vincristine by continuous infusion did not result in objective responses in this group of patients, although when it was evaluated by other investigators (Phase I studies), a few responses were observed in patients with metastatic breast ~arcin0ma.l~-l4 However, no objective response was observed in a recent Phase I1 study. 15 The response rates of vinblastine and vindesine were similar to those of our prior Phase I1 s t u d i e~.~J~ Paresthesia developed in all patients treated with vincristine. Granulocytopenia developed with vindesine in half of the courses given.…”

Section: Discussionsupporting

confidence: 71%

A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma

Yau

Yap²,

Buzdar³

et al. 1985

Cancer

View full text Add to dashboard Cite

The therapeutic efficacy of vincristine, vinblastine, and vindesine were evaluated in a prospective randomized trial in patients with metastatic breast carcinoma. All patients were refractory to doxorubicincontaining chemotherapy. Vincristine was administered at 0.4 mg/M2/I/day by continuous infusion (CI), vinblastine at 1.7 mg/M2/I/day by CI, and vindesine at 1.2 mg/M2/I/day by CI or intermittent bolus (IB) over 5 days. The courses were administered at 2‐week intervals for vincristine and 3‐week intervals for vinblastine and vindesine. Ninety‐nine patients were evaluable for response. The 15 patients treated with vincristine had no objective response. Of 23 patients treated with vinblastine, there were 2 complete responses (9%) and 5 partial responses (22%). Of 31 patients treated with CI vindesine, there were 6 partial responses (19%). Of 30 patients treated with IB vindesine, there were 5 partial responses (17%). The median duration of disease control was 13 weeks (range, 8–140 +) for vinblastine, 18 weeks (range, 8–34) for CI vindesine, and 20 weeks (range, 12–47) for IB vindesine. These data illustrate that vinblastine (CI) and vindesine (CI or IB) have significant antitumor activity in patients with refractory metastatic breast carcinoma and that vincristine has no antitumor activity in similar patients.

show abstract

Section: Discussionsupporting

confidence: 71%

A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma

Yau

Yap²,

Buzdar³

et al. 1985

Cancer

View full text Add to dashboard Cite

show abstract

Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association

Thomas

Muss

Jackson

et al. 1994

Cancer Chemother. Pharmacol.

View full text Add to dashboard Cite

Vincristine (VCR) and etoposide (VP-16) have been shown to be synergistic in a murine model, and this combination was studied in a phase II trial. Eligibility required measurable disease, a performance status of 0-2, a life expectancy of > or = 2 months, an interval of at least 3 weeks since the receipt of previous radiation therapy or chemotherapy and recovery from related toxicity, no prior treatment with VCR or VP-16, and no more than two prior chemotherapy regimens (only one for treatment of metastatic disease). Treatment consisted of 0.5 mg i.v. (bolus) VCR followed by 200 mg/m2 VP-16 given over 2 h. Both drugs were given daily for 3 consecutive days every 3 weeks (total dose: VCR, 1.5 mg; VP-16, 600 mg/m2). A total of 18 patients with metastatic breast cancer were accured; 14 had adjuvant chemotherapy and 8 had chemotherapy for advanced disease. As judged by International Union Against Cancer (UICC) criteria, one complete response (CR) and three partial responses (PR) were obtained, for a CR + PR rate of 22% (95% confidence interval, 6%-48%). All responders had soft-tissue involvement only. Six patients had stable disease and 8 showed progression. The median time to treatment failure was 3.5 months, and the median survival from study entry was 8.3 months. The major toxicity was myelosuppression, with 9 patients (50%) experiencing a total WBC of < 1,000/mm3. Grade 2-3 neurologic toxicity was noted in 6 patients (33%) and grade 3 nausea and vomiting was noted in 5 (28%). The combination of VCR and VP-16 is active in advanced breast cancer but is not convincingly superior to either of these agents used alone.

show abstract

Chemotherapy of breast cancer

Perlow

Holland

1984

Med. Oncol. & Tumor Pharmacother.

View full text Add to dashboard Cite

Vincristine by continuous infusion in refractory breast cancer

Cited by 6 publications

References 0 publications

A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma

A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma

Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association

Chemotherapy of breast cancer

Contact Info

Product

Resources

About